Welcome to our dedicated page for Checkmate Pharmaceuticals news (Ticker: CMPI), a resource for investors and traders seeking the latest updates and insights on Checkmate Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Checkmate Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Checkmate Pharmaceuticals's position in the market.
Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) reported its full year 2020 financial results, highlighting significant advancements in its CMP-001 clinical program targeting melanoma and other solid tumors. As of December 31, 2020, the company had $125.9 million in cash and equivalents. Research and development expenses rose to $26.7 million, attributed to increased headcount and consulting costs. General and administrative expenses also increased to $10.2 million. The net loss for the year was $36.9 million, up from $28.3 million in 2019. Two Phase 2 trials for melanoma are expected to push clinical milestones forward in 2021.
Checkmate Pharmaceuticals (NASDAQ: CMPI) will present new data from its Phase 1b trial of CMP-001 for advanced melanoma at the virtual AACR Annual Meeting, occurring from April 10-15, 2021. The oral presentation, titled "CMP-001 demonstrates improved response in noninflamed anti–PD-1 refractory melanoma and response is associated with serum CXCL10," is scheduled for April 11, 2021, at 4:00 PM ET. Presenting author Jason Luke, MD, will share insights related to the trial's findings, which may enhance treatment strategies using CMP-001 alongside other therapies.
Checkmate Pharmaceuticals announced the appointment of Robert F. Dolski as Chief Financial Officer and Katherine Eade as General Counsel. Dolski brings over 20 years of experience in financial management within the biopharmaceutical industry, while Eade has extensive legal expertise in corporate transactions and governance. Their roles are expected to support Checkmate’s lead program, CMP-001, which is advancing to clinical development. The company's focus remains on using its proprietary technology to enhance immune responses against cancer.
Checkmate Pharmaceuticals (NASDAQ: CMPI) announced a collaboration with Bristol Myers Squibb (NYSE: BMY) to evaluate CMP-001 combined with Opdivo® (nivolumab) for treating unresectable or metastatic melanoma. The collaboration includes two Phase 2 trials: one studying CMP-001 and nivolumab in refractory melanoma patients, and another comparing first-line treatment with CMP-001 and nivolumab against nivolumab alone. Checkmate will sponsor the trials, with Bristol Myers supplying nivolumab, emphasizing their commitment to advancing immunotherapy.
Checkmate Pharmaceuticals (NASDAQ: CMPI) presented new data on CMP-001 at SITC’s 35th Annual Meeting, highlighting its clinical activity in melanoma. The company plans to initiate three Phase 2 trials by late 2020/early 2021, targeting head and neck cancer and melanoma indications. As of Q3 2020, Checkmate reported cash reserves of $137.3 million. R&D expenses rose to $6.7 million, reflecting increased trial activities, while G&A expenses climbed to $3.2 million. The net loss for the quarter was $9.8 million, an increase from $6.2 million in Q3 2019.
Checkmate Pharmaceuticals, a clinical-stage biotechnology firm developing immune-based cancer therapies, announced that CEO Barry Labinger will present at the Jefferies Virtual London Healthcare Conference on November 17, 2020, from 6:45 to 7:15 am ET. The presentation will be webcast live, with an archived copy available on Checkmate's website for 45 days post-event. Checkmate's lead product, CMP-001, is a TLR9 agonist aimed at enhancing the immune response against tumors when used with other therapies.
Summary not available.
Checkmate Pharmaceuticals (NASDAQ: CMPI) announced its second quarter 2020 financial results and progress updates. The company raised approximately $76.6 million in its recent IPO, completing it in August 2020. Checkmate is poised to initiate key clinical trials combining CMP-001 with checkpoint inhibitors targeting melanoma and head and neck cancers by late 2020/early 2021. Cash and cash equivalents stood at $80.3 million as of June 30, 2020. However, the company reported a net loss of $8.3 million for the quarter, increasing from $6.9 million in the previous year.
Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) has announced the pricing of its initial public offering (IPO) of 5,000,000 shares at $15.00 each, aiming to raise approximately $75 million before expenses. The shares will trade on Nasdaq starting August 7, 2020, with the offering expected to close on August 11, 2020. Underwriters have a 30-day option to purchase an additional 750,000 shares. The funds will support Checkmate's proprietary cancer therapy development, CMP-001, which utilizes the immune system to fight cancer.